Cartesian Therapeutics (RNAC) Accumulated Depreciation & Amortization: 2015-2025
Historic Accumulated Depreciation & Amortization for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $4.1 million.
- Cartesian Therapeutics' Accumulated Depreciation & Amortization fell 34.67% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.9 million, marking a year-over-year decrease of 45.90%. This contributed to the annual value of $2.4 million for FY2024, which is 58.85% down from last year.
- According to the latest figures from Q3 2025, Cartesian Therapeutics' Accumulated Depreciation & Amortization is $4.1 million, which was up 17.16% from $3.5 million recorded in Q2 2025.
- In the past 5 years, Cartesian Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $6.3 million in Q3 2024 and a low of $2.4 million during Q4 2024.
- In the last 3 years, Cartesian Therapeutics' Accumulated Depreciation & Amortization had a median value of $5.6 million in 2023 and averaged $4.9 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first rose by 15.68% in 2023, then plummeted by 58.85% in 2024.
- Cartesian Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $4.8 million in 2021, then increased by 8.51% to $5.2 million in 2022, then rose by 10.05% to $5.7 million in 2023, then slumped by 58.85% to $2.4 million in 2024, then tumbled by 34.67% to $4.1 million in 2025.
- Its last three reported values are $4.1 million in Q3 2025, $3.5 million for Q2 2025, and $2.9 million during Q1 2025.